Introduction
============

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second most common contributing factor to cancer mortality rates worldwide ([@b1-mmr-17-02-2211]--[@b4-mmr-17-02-2211]). Although progress has been made in diagnostic and therapeutic strategies, the prognosis of patients with advanced HCC remains unsatisfactory, primarily due to its frequent recurrence and metastases ([@b5-mmr-17-02-2211]--[@b9-mmr-17-02-2211]). The 5-year survival rate has been previously reported to be 25--39% following resection ([@b10-mmr-17-02-2211]--[@b13-mmr-17-02-2211]). Therefore, it is necessary to investigate the underlying molecular mechanisms in the development of HCC to identify novel diagnostic markers and innovative therapeutic targets for patients with HCC.

MicroRNAs (miRNAs), a class of small, endogenous, single-stranded, non-coding RNAs, are 18--25 nucleotides in length and can alter gene expression. The aberrant expression of miRNAs can directly induce multiple diseases, including cancer. miRNAs have been used as non-invasive tumor biomarkers as they are involved in differentiation, proliferation and apoptosis in various malignancies ([@b14-mmr-17-02-2211]--[@b17-mmr-17-02-2211]). In HCC, the abnormal expression of miRNAs is essential during the progression of HCC ([@b18-mmr-17-02-2211]--[@b21-mmr-17-02-2211]). As reported, several miRNAs with lower expression levels can act as tumor suppressors in HCC tumorigenesis and growth ([@b22-mmr-17-02-2211]--[@b27-mmr-17-02-2211]), whereas certain upregulated miRNAs may function as HCC activators ([@b28-mmr-17-02-2211]--[@b31-mmr-17-02-2211]).

miR-223-3p is an miRNA, which has been identified in human diseases in previous studies. In penile carcinoma, the overexpression of miR-223-3p was considered a molecular classifier to differentiate tumors from non-cancerous tissues ([@b32-mmr-17-02-2211]). The upregulation of miR-223-3p may be a potential diagnostic biomarker in esophageal squamous cell carcinoma ([@b33-mmr-17-02-2211]). In addition, downregulated levels of miR-223-3p are closely associated with poor prognosis in bladder cancer ([@b34-mmr-17-02-2211]). In HCC, cell proliferation is enhanced by low expression levels of miR-223-3p ([@b35-mmr-17-02-2211]). A number of studies have also reported that downregulated miR-223-3p is a potentially favorable biomarker for early-stage diagnosis of HCC ([@b36-mmr-17-02-2211]--[@b38-mmr-17-02-2211]). However, certain studies have revealed that miR-223-3p is preferentially expressed in HCC, compared with healthy controls ([@b39-mmr-17-02-2211],[@b40-mmr-17-02-2211]). Although it is maintained that circulating miR-223-3p can provide a certain degree of diagnostic accuracy in patients with HCC ([@b41-mmr-17-02-2211],[@b42-mmr-17-02-2211]), reports on the diagnostic value for HCC in serum and tissues remain limited. Therefore, the present study aimed to perform a more comprehensive meta-analysis of the diagnostic value of miR-223-3p and precursor miR-223, based on data extracted from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and qualified literature.

miR-223-3p can directly target different genes and signaling pathways in a diverse set of diseases. For example, in non-small-cell lung cancer (NSCLC), an increased level of miR-223-3p induces the downregulation of insulin-like growth factor 1 receptor (IGF1R), which may indicate a potential therapeutic strategy for tyrosine kinase inhibitor-resistant NSCLC ([@b43-mmr-17-02-2211]). The invasiveness of bladder carcinoma can be suppressed by targeting nuclear receptor coactivator 1 (NCOA1) by miR-223-3p ([@b34-mmr-17-02-2211]). In addition, miR-223-3p can target stathmin 1 (STMN1) and IGF1R in gastric carcinoma to inhibit tumor progression ([@b44-mmr-17-02-2211]). A previous study also reported that miR-223-3p accelerated the development of HCC through mediating the G2/M transition by targeting STMN1 ([@b45-mmr-17-02-2211]), and miR-223-3p inhibits the onset and progression of HCC by repressing the gene expression of c-Myc ([@b46-mmr-17-02-2211]). However, the potential mechanisms underlying the activity of miR-223-3p in HCC remain to be fully elucidated. Therefore, the specific molecular mechanisms by which miR-223-3p is involved in the occurrence and development of HCC requires investigation. The present study aimed to clarify the role of miR-223-3p in HCC tumorigenesis. The use of high-throughput data, including microarray and RNA-sequencing, and bioinformatics may provide novel insights into how miR-223-3p functions in HCC, and to provide a theoretical foundation for the diagnosis and personalized therapy of patients with HCC.

Materials and methods
=====================

Clinical significance: GEO database
-----------------------------------

### Mining expression profiles from microarrays

The HCC microarray profiles were obtained from the National Center for Biotechnology Information GEO (<http://www.ncbi.nlm.nih.gov/geo/>) based on the following search strategy: '(miR or microRNA or miRNA) and (malignan\* or cancer or tumor or tumour or neoplas\* or carcinoma) and (hepatocellular or liver or hepatic OR HCC)'. The search included all terms that begin with a word by entering the word followed by an asterisk (\*), the wildcard character. Data including the expression level of miR-223-3p in human HCC and in non-cancerous controls were collected.

### Manufacturing receiver operating curve (ROC) and scatter plots of the expression of miR-223-3p

Based on the expression level of miR-223-3p, ROC and scatter plots were separately produced in GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). The sensitivity and specificity of miR-223-3p in HCC were also evaluated for meta-analysis.

### Statistical analysis

SPSS software (version 22.0; IBM Corp., Armonk, NY, USA) was used to conduct statistical analysis. The expression profiles from the GEO were normalized by log2-transformation. The expression of miR-223-3p was calculated as the mean ± standard deviation. An independent Student\'s t-test was performed to calculate the difference between HCC cases and non-cancerous tissues. P\<0.05 was considered to indicate a statistically significant difference.

Clinical significance: TCGA database
------------------------------------

### TCGA data

To further clarify the correlations between the precursor miR-223 and HCC, the reads per million (RPM) miRNA mapped data of miR-223 in 375 HCC and 50 non-cancerous liver tissues were scanned and extracted from the TCGA database (<http://cancergenome.nih.gov>). Additionally, the raw mRNA count (level 3) and the corresponding clinical information of the 375 patients with HCC were obtained.

### Analyzing the clinical features of miR-223

For determining the miR-223-expressing conditions in the different clinicopathological features of HCC, scatter plots were constructed. The Kaplan-Meier curve was used to examine the prognostic value of miR-223 in HCC.

### Statistical analysis

The mRNA expression level values were normalized by conversion to a log2 scale using the edgeR package of R software (version 3.5; <http://www.bioconductor.org/packages/release/bioc/html/edgeR.html>), in addition to the RPM data. The mRNAs with an absolute log2-fold change \>2 were identified as differentially expressed. The differences in the levels of miR-223 between various clinical features were assessed using an independent Student\'s t-test. P\<0.05 was considered to indicate a statistically significant difference.

### Identification of diagnostic accuracy from eligible studies

A literature search (up to 09/05/2017) was performed using the following databases: PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), EBSCO (<https://www.ebsco.com>), Wiley Online Library (<http://onlinelibrary.wiley.com>), Web of Science (<http://isiknowledge.com>), Science Direct (<http://www.sciencedirect.com>), Cochrane Central Register of Controlled Trials (<http://www.cochranelibrary.com>), Google Scholar (<https://scholar.google.com>), EMBASE (<https://www.embase.com>), Ovid (<http://ovidsp.ovid.com>) and LILACS (<http://lilacs.bvsalud.org>), in addition to the following Chinese databases: Chinese CNKI (<http://www.cnki.net>), Chinese Chong Qing VIP (<http://lib.cqvip.com>), Chinese Wan Fang (<http://www.wanfangdata.com.cn>) and China Biology Medicine disc (<http://www.sinomed.ac.cn>). The search strategy was as follows '(miR-223 or miRNA-223 or microRNA-223 or miR223 or miRNA223 or microRNA223 or miR 223 or miRNA 223 or microRNA 223 or miR-223 or miRNA-223-3p or microRNA-223-3p) and (malignan\* or cancer or tumor or tumour or neoplasm\*, or carcinoma) and (hepatocellular or liver or hepatic or HCC). The inclusion criteria were as follows: i) Studies evaluating the diagnostic value of downregulated miR-223-3p (or miR-223) in serum, plasma or HCC tissues; ii) studies providing sufficient information for calculating the sensitivity and specificity of miR-223-3p (or miR-223) for diagnosing HCC; and iii) studies published in English or Chinese. For eligible studies with data published more than once, those with the largest patient sample size were included. In addition, the following exclusion criteria were used: i) Studies detecting miR-223-3p (or miR-223) in cell lines or animals; ii) results published as an abstract, summary, case report, comment letter, review or editorial; and iii) studies without sufficient data for evaluating the diagnostic value of miR-223-3p (or miR-223) in human HCC.

The quality assessment of literature was performed independently by two authors (Ms. Li-jie Zhang and Ms. Mei-Ling Yang) using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 Tool ([www.bris.ac.uk/quadas](www.bris.ac.uk/quadas)). A discussion of consistency was applied when divergence appeared. QUADAS-2 was used to judge bias and applicability between 'high' and 'low' risks, which consisted of patient selection, index test, reference standard, and flow and timing ([@b47-mmr-17-02-2211]).

### Meta-analysis

Stata (version 12.0; StataCorp, College Station, TX, USA) to conduct the meta-analysis. The 'midas' module of Stata 12.0 (StataCorp LP, College Station, TX, USA) was used to combine the diagnostic data from GEO, TCGA and the literature. The heterogeneity was calculated using a χ^2^ test and I^2^, and I^2^\>50% or/and P\<0.05 for the Q test were considered to be statistically significant in heterogeneity. The fixed-effect model was used if there was significant heterogeneity. Otherwise, the random effect model was used ([@b48-mmr-17-02-2211]). The summarized indices included sensitivity, specificity, likelihood ratio and diagnostic odds ratio with a 95% confidence interval (CI). Based on the sensitivity and specificity, a summary receiver operating characteristic curve (SROC) was used for evaluation. Publication bias was measured by plotting Deek\'s funnel plot ([@b49-mmr-17-02-2211]). P\<0.05 (two-sided) was considered to indicate a statistically significant difference

Bioinformatics evaluation
-------------------------

Selection of potential target genes. The targets of miR-223-3p were selected from the intersection of 13 prediction tools, natural language processing (NLP) of HCC, and differentially expressed genes from TCGA. A total of 12 online tools were used for predicting potential targets: miRWalk (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2>), Micro T4 (<http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=microtv4/index>), miRanda (<http://www.microrna.org/microrna/getDownloads.do>), miRBridge (<https://www.ncbi.nlm.nih.gov/pubmed/?term=20385095>), miRDB (<http://mirdb.org/miRDB/download.html>), miRMap (<http://mirmap.ezlab.org/downloads/mirmap201301e/>), miRNAMap (<ftp://mirnamap.mbc.nctu.edu.tw/miRNAMap2>), PICTAR2 (<http://dorina.mdc-berlin.de/rbp_browser/download_hg19.html>), PITA (<https://genie.weizmann.ac.il/pubs/mir07/mir07_exe.html>), RNA22 (<https://cm.jefferson.edu/rna22/>), RNAhybrid (<https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid/dl_pre-page.html>), and TargetScan (<http://www.targetscan.org/cgi-bin/targetscan/data_download.cgi?db=vert_61>). The genes found to overlap on at least three prediction programs were identified as targets. The predicted targets of miR-223-3p in the miTarBase program were confirmed using western blot analysis and quantitative polymerase chain reaction reporter assays. Genes expressed aberrantly in HCC in studies published between 01/01/1980 and 05/25/2015 were gathered with NLP techniques, as described in our previous study ([@b50-mmr-17-02-2211]). Additionally, the extracted genes were added to a list using ABNER (<http://pages.cs.wisc.edu/~bsettles/abner/>) ([@b51-mmr-17-02-2211]). The correlations between hub genes and miR-223-3p were assessed using Spearman\'s correlation.

### Prospective mechanisms and functions

The molecular mechanisms and biological functions of potential miR-223-3p targets in HCC were identified by enrichment analysis and pathway annotations. Gene Ontology (GO) analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID; <https://david.ncifcrf.gov/>). P\<0.05 was considered to indicate a significant pathway. GO associations were also visualized in Cytoscape (version 3.4.0; <http://www.cytoscape.org/>).

### Protein-protein interaction (PPI) network construction

The potential targets were mapped to the Search Tool for the Retrieval of Interacting Genes database (<http://www.string-db.org/>) ([@b52-mmr-17-02-2211]) to evaluate significant correlations between different protein pairs. The overall design of the present study is shown in the flow chart in [Fig. 1](#f1-mmr-17-02-2211){ref-type="fig"}.

Results
=======

### Expression of miR-223-3p in HCC in GEO

A total of 15 series (GSE) in the GEO database were extracted for the present study, which consisted of 706 HCC samples and 457 normal controls. In addition to GSE21279, detecting the expression level of the precursor miR-223, the other 14 GEO accessions were all identified as miR-223-3p expression profiles. Detailed information regarding each GEO accession is shown in [Table I](#tI-mmr-17-02-2211){ref-type="table"}. The expression level of miR-223-3p was significantly downregulated in patients with HCC in seven of the 15 GEO datasets ([Fig. 2A-O](#f2-mmr-17-02-2211){ref-type="fig"}). Compared with the non-cancerous controls, the miR-223-3p HCC expression profiles were significantly downregulated in GSE54751, GSE12717, GSE39678, GSE74618, GSE6857, GSE65708 and GSE21362 (P\<0.05). By contrast, the expression level of miR-223-3p in GSE50013 was upregulated in HCC groups (P=0.015). The levels of miR-223-3p were also obtained based on TCGA expression profiles. In liver HCC, the levels of miR-223-3p in cancer tissues were also lower, compared with those in the normal controls ([Fig. 3A](#f3-mmr-17-02-2211){ref-type="fig"}).

The ROC analysis revealed a significant diagnostic value of miR-223-3p for HCC. Of the 15 GEO profiles, five with an AUC \>0.80 are shown in [Fig. 3B-a-e](#f3-mmr-17-02-2211){ref-type="fig"} (P\<0.05).

### Expression of miR-223 in HCC in TCGA

A total of 371 patients with HCC (252 men and 119 women) and 50 normal controls were derived from the TCGA dataset. The results from the ROC analysis for TCGA RNA-seq data are shown in [Fig. 3B-f](#f3-mmr-17-02-2211){ref-type="fig"} (AUC, 0.78; 95% CI, 0.74--0.83; P\<0.001). Additionally, the present study analyzed the associations between the level of miR-223 and the clinical features of patients with HCC. As is shown in [Fig. 4A-a](#f4-mmr-17-02-2211){ref-type="fig"}, there was a significant difference in the expression of miR-223 between the HCC tissues (9.112±1.436) and healthy controls (10.300±0.811; P\<0.001). However, no statistically significant correlations were found between the level of miR-223 and various clinicopathological features of the patients with HCC ([Fig. 4A-b-f](#f4-mmr-17-02-2211){ref-type="fig"}; [Table II](#tII-mmr-17-02-2211){ref-type="table"}). The effect of the expression of miR-223 on survival outcomes in HCC was also insignificant (P=0.201 for overall survival, P=0.263 for disease free survival; [Fig. 4B](#f4-mmr-17-02-2211){ref-type="fig"}).

### Inclusion of previous literature and quality assessment

A total of 295 relevant studies were identified in the literature search, and 100 were excluded due to duplicated publications. In total, three publications, comprising six studies with sufficient data, were eventually considered to be eligible for analysis in the present study. The detailed characteristics are shown in [Table III](#tIII-mmr-17-02-2211){ref-type="table"}. The results of the quality assessment of the literature are shown in [Table IV](#tIV-mmr-17-02-2211){ref-type="table"}.

Meta-analysis for diagnostic value of miR-223-3p in HCC
-------------------------------------------------------

### Pooled diagnostic performance

The diagnostic accuracy of miR-223-3p and miR-223 for HCC was pooled from 19 studies ([Table V](#tV-mmr-17-02-2211){ref-type="table"}). The I^2^ value for the AUC was 0.97 (95% CI, 0.95--0.99), therefore, a random model was used in the following analysis. The overall pooled sensitivity was 0.80 with a 95% CI between 0.69 and 0.88, whereas the specificity was 0.83 with a 95% CI between 0.75 and 0.89 ([Fig. 5A](#f5-mmr-17-02-2211){ref-type="fig"}). The positive and negative likelihood ratios were 4.8 (95% CI, 3.1--7.2) and 0.24 (95% CI, 0.15--0.39), respectively. Overall, the diagnostic odds ratio was 19 (95% CI, 10.0--39.0). The diagnostic accuracy was further evaluated by plotting the SROC, and by calculating the AUC, which was 0.89 (95% CI, 0.85--0.91), indicating a high diagnostic accuracy in distinguishing patients with HCC from healthy controls ([Fig. 5B](#f5-mmr-17-02-2211){ref-type="fig"}).

### Univariate regression and subgroup analysis

As the threshold effect accounted for only 5% of the heterogeneity across a total of 19 studies, univariate regression and subgroup analysis was used to further investigate the sources of heterogeneity. The sample type (serum or tissues) and histological type for the controls may contribute to heterogeneity. The sample type was ultimately revealed to be a statistically significant source of heterogeneity (P\<0.001; [Fig. 6A](#f6-mmr-17-02-2211){ref-type="fig"}).

### Publication bias

Publication bias in the present study was determined using Deek\'s funnel plot, and the P-value (P=0.054), indicated no statistical significance in publication bias ([Fig. 6B](#f6-mmr-17-02-2211){ref-type="fig"}).

Potential mechanisms and functions of miR-223-3p in HCC
-------------------------------------------------------

### Potential target genes of miR-223-3p

Based on the 12 online predictive tools mentioned above, a total of 12,821 genes, which appeared on three or more platforms, were screened, and 48 validated genes were obtained from miTarBase. In addition, 1,800 genes associated with HCC were identified from 64,577 studies in the processing of NLP, and 2,155 upregulated genes in HCC were identified from TCGA in the present study. Finally, 72 genes, which intersected in the three aforementioned methods, were included in further analysis.

### Pathway annotation of KEGG

From the KEGG pathway annotation, a total of 11 pathways were identified (listed in [Table VI](#tVI-mmr-17-02-2211){ref-type="table"}). The pathways with significantly different gene counts are shown in [Fig. 7](#f7-mmr-17-02-2211){ref-type="fig"} (P\<0.05). The highest degree of significance was in 'microRNAs in cancer' (P\<0.001). The genes DNA methyltransferase 1 (DNMT1), kinesin family member 23 (KIF23), STMN1 and others are involved in this pathway. Additionally, several potential target genes were closely associated with KEGG pathways, including the terms 'pathways in cancer' (P\<0.001), 'prostate cancer' (P\<0.001) and 'cell cycle' (P=0.003).

### Biological functional analysis of GO

A total of 43 significant GO categories were screened out using DAVID, including 29 biological processes (BPs), nine cellular components (CCs) and five molecular functions (MFs). The top 10 significant analyses of BPs are shown in [Table VII](#tVII-mmr-17-02-2211){ref-type="table"}, in addition to the nine CCs and five MFs (P\<0.05). The results showed that, in the BP category, potential targets of miR-223-3p were concentrated predominantly on the terms 'mitotic cytokinesis' (P\<0.001), 'positive regulation of cytokinesis' (P\<0.001) and 'negative regulation of transcription from RNA polymerase II promoter' (P=0.003; [Fig. 8](#f8-mmr-17-02-2211){ref-type="fig"}). For the CCs, the target genes were predominantly enriched in the terms 'centralspindlin complex' (P\<0.001), 'microtubule' (P=0.001) and 'midbody' (P=0.006; [Fig. 9](#f9-mmr-17-02-2211){ref-type="fig"}). In the MF category ATP binding' was the most enriched term (P=0.003), followed by 'chromatin binding' (P=0.008) and 'armadillo repeat domain binding' (P=0.02; [Fig. 10](#f10-mmr-17-02-2211){ref-type="fig"}).

### PPI network construction

A PPI network of the 72 potential targets of miR-223-3p was mapped ([Fig. 11](#f11-mmr-17-02-2211){ref-type="fig"}). The 10 protein pairs with the highest combined scores are listed in [Table VIII](#tVIII-mmr-17-02-2211){ref-type="table"}. The five genes, which interacted \>5 times between different protein pairs were identified as the hub genes of miR-223-3p, including checkpoint kinase 1 (CHEK1), DNA methyltransferase 1 (DNMT1), baculoviral IAP repeat containing 5 (BIRC5), KIF23 and collagen, type I, α1 (COL1A1). In TCGA, compared with the normal controls, all five of these targets were significantly upregulated in HCC (P\<0.05). Additionally, correlations of the hub genes and miR-223 were also shown in [Figs. 12](#f12-mmr-17-02-2211){ref-type="fig"} and [13](#f13-mmr-17-02-2211){ref-type="fig"}. High expression levels of the gene COL1A1 were significantly correlated with a lower level of miR-223 in HCC (P=0.001; [Fig. 13B-b](#f13-mmr-17-02-2211){ref-type="fig"}).

Discussion
==========

The results of the present study indicated that miR-223-3p may be a tumor suppressor and a preferable diagnostic biomarker for HCC. A decreased frequency of miR-223-3p was shown in HCC samples in the GEO datasets, and the precursor miR-223 was downregulated in HCC samples in the TCGA database. The AUC of the SROC for miR-223-3p in diagnosing HCC was 0.89 (95% CI 0.85--0.91). From the PPI network, five potential targets were identified as the hub genes of miR-223-3p, including CHEK1, DNMT1, BIRC5, KIF23 and COL1A1.

Previous studies have found that miR-223-3p can act as an important novel biomarker for cancer screening in peripheral circulating blood and tissues. However, whether the miR-223-3p is downregulated in tumorigenesis or not remains controversial. The reduced expression of miR-223-3p in plasma may be a novel non-invasive detector in esophageal squamous cell carcinoma ([@b33-mmr-17-02-2211]), and abnormalities in the expression of miR-223-3p in patients with HCC have enabled discrimination from normal controls. Compared with normal controls, the marked decrease in circulating miR-223-3p in HCC may serve as a biomarker ([@b36-mmr-17-02-2211],[@b38-mmr-17-02-2211],[@b55-mmr-17-02-2211],[@b56-mmr-17-02-2211]). By contrast, in ovarian cancer tissues, miR-233-3p is expressed at high levels, particularly in recurrent cancer tissues ([@b57-mmr-17-02-2211]). In gingival squamous cell carcinoma, significantly upregulated plasma levels of miR-223-3p have been identified as a diagnostic biomarker ([@b58-mmr-17-02-2211]). miR-223-3p was also found to be at a higher level in the serum of patients with chronic hepatitis-related HCC ([@b39-mmr-17-02-2211]). As reports on the expression of miR-223-3p in HCC have been controversial, the present study used GEO and TCGA datasets to perform a detailed analysis of the expression profiles of miR-223-3p or its processor miR-223 in HCC samples, compared with non-cancerous controls. A significant downregulation of miR-223-3p in HCC was reported in the majority of the studies included. With a total of 1,170 HCC samples in the present study, further large-sample analyses are required.

As miRNAs exist stably in the circulation, including the serum, plasma and urine, miR-223-3p may also be used as a blood-based tumor marker for diagnosing HCC in its early stages. In the present study, a comprehensive diagnostic meta-analysis was performed, which focused on circulating miR-223-3p and on miR-223-3p expression profiles in HCC tissues. The AUC of SROC was 0.89, which represents moderate accuracy for a diagnosis of HCC ([@b59-mmr-17-02-2211]). In accordance with the present study, Li *et al* found that circulating miR-223-3p in HCC was an informative biomarker, with the AUC of SROC being 0.8597 ([@b41-mmr-17-02-2211]). The limitation of the study by Li *et al* was that only one study with only 101 HCC serum samples had been included, whereas 19 studies comprising 1,170 HCC samples were used in the present study. The levels of miR-223-3p were closely correlated with HCC in fresh tissues and formalin-fixed paraffin-embedded (FFPE) samples. The expression of miR-223-3p was deregulated in FFPE HCC samples, with a sensitivity of 78.6% and a specificity of 72.7%. Additionally, downregulated miR-223-3p may act as a biomarker for HCC prognosis following orthotopic liver transplantation ([@b60-mmr-17-02-2211]). Therefore, it may be possible to diagnose HCC by detecting miR-223-3p in tissue biopsies. Additional large-sample clinical studies are required to clarify the clinical significance of the association between miR-223-3p and HCC.

Previous studies have revealed that miR-223-3p is associated with different diseases. In prostate cancer, miR-223-3p targeted septin 6 to promote cell proliferation, cell apoptosis, cell invasion and other processes ([@b61-mmr-17-02-2211]). NCOA1 and zinc finger E-box-binding homeobox 1 protein translation may be mediated by miR-223-3p to inhibit the migration and invasion of human bladder cancer cells ([@b34-mmr-17-02-2211],[@b62-mmr-17-02-2211]). miR-223-3p may reflect changes in inflammation, vascular calcification and pathophysiology of bones ([@b63-mmr-17-02-2211]). As a tumor suppressor, enhanced levels of miR-223-3p inhibited tumorigenesis and metastasis in HCC. miR-223-3p can promote HCC cell apoptosis through the mammalian target of rapamycin pathway ([@b64-mmr-17-02-2211],[@b65-mmr-17-02-2211]). miR-223-3p may also be key in cell proliferation and exert tumor-suppressive effects on hepatitis B virus-related HCC ([@b35-mmr-17-02-2211]). In addition, the overexpression of miR-223-3p can increase HCC cell sensitivity to anticancer drugs by repressing ATP-binding cassette sub-family B member 1 at the mRNA and protein levels ([@b66-mmr-17-02-2211]). These results demonstrate the multiple functions of miR-223-3p in HCC.

The five hub genes of miR-223-3p identified in the present stud were further analyzed by investigating potential molecular mechanisms and the tumorigenesis of HCC. The hub genes CHEK1, DNMT1, BIRC5, KIF23 and COL1A1 were all significantly upregulated in HCC tissues, compared with non-cancerous controls. By contrast, miR-223-3p was present at a decreased level in HCC tissues. The AUC of SROC for miR-223-3p in diagnosing HCC was 0.89. Therefore, the lower level of miR-223-3p may target these important hub genes in certain pathways. For example, the CHEK1 gene was involved in the cell cycle pathway, KIF23 and DNMT1 were enriched at microRNA levels in cancer pathways, BIRC5 was identified in cancer pathways and COL1A1 was identified in the collagen fibril organization pathway. These five hub genes may be pivotal in HCC.

As a novel tumor suppressor, CHEK1 is involved in tumor prevention and therapeutics ([@b67-mmr-17-02-2211]). However, the upregulation of CHEK1 in HCC may have a tumorigenic function, and the overexpression of CHEK1 may be a reliable diagnostic indicator in patients with HCC. Therefore, targeting the CHEK1/SYK(L) pathway may be a promising therapeutic strategy for treating HCC ([@b68-mmr-17-02-2211],[@b69-mmr-17-02-2211]). DNMT1 is involved in tumorigenesis and cancer progression ([@b70-mmr-17-02-2211]). A high expression level of DNMT1 has been associated with HCC-related growth factors. This high level of expression indirectly mediates the progression of HCC caused by hepatitis B virus infection ([@b71-mmr-17-02-2211],[@b72-mmr-17-02-2211]). In addition, the upregulation of DNMT1 has been associated with recurrence and poor outcome of HCC cases ([@b73-mmr-17-02-2211]). The KIF23 gene acts an important regulator in cytokinesis ([@b74-mmr-17-02-2211]). The upregulation of KIF23 leads to the earlier recurrence of HCC ([@b75-mmr-17-02-2211]). Therefore, DNMT1 and KIF23 may provide valuable information on the prognosis of patients with HCC. BIRC5 is known as an apoptosis inhibitor protein in malignancies; therefore BIRC5 may be a valuable diagnostic factor for HCC. The co-suppression of OCT4/BIRC5 is beneficial for treating patients with HCC ([@b76-mmr-17-02-2211],[@b77-mmr-17-02-2211]), and COL1A1 is an important the target in hepatic fibrosis, having been confirmed as a potential prognostic biomarker in HCC ([@b78-mmr-17-02-2211]--[@b80-mmr-17-02-2211]). Of note, in the present study, the upregulation of COL1A1 was significantly correlated with the downregulation of miR-223 (r=−0.178; P=0.001), which indicated that COL1A1 may also be a potential diagnostic biomarker in HCC.

In conclusion, increasing evidence has revealed that the hub genes of miR-223-3p can directly or indirectly regulate the occurrence, progression, diagnosis, prognosis and treatment of HCC. However, the present study did not experimentally validate the correlations between miR-223-3p and its hub genes. A number of these hub genes had limited reports with miR-223-3p in HCC. In the future, the predicted hub genes, which were identified from the PPI analysis, require validation in *in vivo* and *in vitro* experiments.

In the present study, a decreased level of miR-223-3p in HCC was markedly associated with its diagnostic value, possibly by targeting potential genes in different biological pathways. Therefore, the present study revealed that miR-223-3p merits attention as a significant biomarker in the diagnostic setting and tumorigenesis of HCC. Additional experiments and analyses are required to confirm the potential molecular mechanisms and the prognostic role of miR-223-3p in HCC.
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![Flow chart of the method used in the present study. HCC, hepatocellular carcinoma; GEO, Gene Expression Omnibus; miR, microRNA; TCGA, The Cancer Geneome Atlas; GO, Gene Ontology; NLP, natural language processing; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPI, protein-protein interaction.](MMR-17-02-2211-g00){#f1-mmr-17-02-2211}

![Expression levels of miR-223-3p in HCC tumor samples from the GEO. Labels in yellow represent significant downregulation of miR-223-3p in HCC tissues in seven cohorts. (A) GSE54751; (B) GSE12717; (C) GSE39678; (D) GSE50013; (E) GSE74618; (F) GSE6857; (G) GSE65708; (H) GSE21362; (I) GSE41874; (J) GSE20971; (K) GSE21279; (L) GSE40744; (M) GSE69580; (N) GSE57555; (O) GSE67882. GEO, Gene Expression Omnibus; HCC, hepatocellular carcinoma; miR, microRNA.](MMR-17-02-2211-g01){#f2-mmr-17-02-2211}

![Expression profiles. (A) TCGA expression profiles of miR-223-3p in different diseases. The light green bars represent cancer tissues. The dark green bars represent normal tissues. ACC, adenoid cystic carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; FPPP, Formalin-fixed Paraffin Pilot Project; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, chromophobe renal cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell cancer; THCA, papillary thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; TCGA, The Cancer Genome Atlas; RPM, reads per million. (B) miR-223-3p ROC curves in GEO and TCGA datasets. (a) ROC of GSE54751; (b) ROC of GSE12717; (c) ROC of GSE39678; (d) ROC of GSE57555; (e) ROC of GSE21362; (f) ROC of TCGA dataset. ROC, receiver operating characteristic; GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.](MMR-17-02-2211-g02){#f3-mmr-17-02-2211}

![Expression level of miR-223 is not significantly correlated with various clinicopathological features of patients with HCC. (A) Expression level of miR-233 in different (a) tissue types in TCGA dataset, (b) stages of HCC, (c) vaso-invasion, (d) size or direct extent of the primary tumor, (e) degree of spread to regional lymph nodes, and (f) presence of distant metastasis. (B) Kaplan-Meier plots of (a) overall survival (months) and (b) disease free survival (months). HCC, hepatocellular carcinoma; miR, microRNA; TCGA, The Cancer Genome Atlas.](MMR-17-02-2211-g03){#f4-mmr-17-02-2211}

![(A) Forest plot of sensitivities and specificities from the test accuracy of circulating miR-223-3p in the diagnosis of HCC; (B) SROC curves for miR-223-3p in the diagnosis of HCC. The identity of cases shown in correspond to those listed in [Table V](#tV-mmr-17-02-2211){ref-type="table"} in order. HCC, hepatocellular carcinoma; miR, microRNA; SROC, summary receiver operating characteristic; AUC, area under the curve; SENS, sensitivity; SPEC, specificity.](MMR-17-02-2211-g04){#f5-mmr-17-02-2211}

![(A) Forest plots for univariable meta-regression and subgroup analyses for sensitivity and specificity. (B) Funnel plot for the assessment of potential publication bias in miR-223-3p assays. The cases shown correspond to those listed in [Table V](#tV-mmr-17-02-2211){ref-type="table"} in order. miR, microRNA.](MMR-17-02-2211-g05){#f6-mmr-17-02-2211}

![Eleven significant KEGG pathways for miR-223-3p targets in hepatocellular carcinoma. miR, microRNA; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-17-02-2211-g06){#f7-mmr-17-02-2211}

![BP category enrichment analysis of potential targets of miR-223-3p. P\<0.005 was selected as the significance threshold to ascertain the reliability of the results. Each node denotes a different BP. The lines represent interactions between several different BPs. miR, microRNA; BP, biological process.](MMR-17-02-2211-g07){#f8-mmr-17-02-2211}

![CC category enrichment analysis of potential targets of miR-223-3p. P\<0.005 was selected as the significance threshold to ascertain the reliability of the results. Each node represents a different CC. The lines show interrelations between different CCs. miR, microRNA; CC, cellular component.](MMR-17-02-2211-g08){#f9-mmr-17-02-2211}

![MF category enrichment analysis of potential targets of miR-223-3p. P\<0.005 was selected as the significance threshold to ascertain the reliability of the results. Each node indicates a different MF. The lines reveal multiple associations between various MFs. miR, microRNA; MF, molecular function.](MMR-17-02-2211-g09){#f10-mmr-17-02-2211}

![Protein-protein interaction network of potential target genes of microRNA-223-3p. The nodes represent various predicted genes. The lines are interactions between nodes.](MMR-17-02-2211-g10){#f11-mmr-17-02-2211}

![Expression conditions of the 3 miR-223-3p hub genes in HCC and their correlations with miR-223. (A-a) Levels of CHEK1 in HCC tissues and healthy controls and (b) correlations between CHEK1 and miR-223. (B-a) Levels of DNMT1 in HCC tissues and non-cancerous controls and (b) correlations between DNMT1 and miR-223. (C-a) Levels of BIRC5 in HCC tissues and non-cancerous controls and (b) correlations between BIRC5 and miR-223. HCC, hepatocellular carcinoma; miR, microRNA; CHEK1, checkpoint kinase 1; DNMT1, DNA methyltransferase 1; BIRC5, baculoviral IAP repeat containing 5.](MMR-17-02-2211-g11){#f12-mmr-17-02-2211}

![Expression conditions of the 2 miR-223-3p hub genes in HCC and their correlations with miR-223. (A-a) Levels of KIF23 in HCC tissues and non-cancerous controls and (b) correlations between KIF23 and miR-223. (B-a) Levels of COL1A1 in HCC tissues and non-cancerous controls and (b) correlations between COL1A1 and miR-223. HCC, hepatocellular carcinoma; miR, microRNA; KIF34, kinesin family member 23; COL1A1, collagen, type I, α1.](MMR-17-02-2211-g12){#f13-mmr-17-02-2211}

###### 

Fifteen gene expression omnibus series datasets of HCC.

             HCC     Non-cancerous                          
  ---------- ------- --------------- ------- -------------- ---------
  GSE57555       5   0.013±0.032       16    0.275±0.540    0.300
  GSE69580       5   4.337±1.241         5   4.677±0.483    0.951
  GSE54751     10    0.412±0.323       10    1.314±0.848    0.006
  GSE41874       6   0.855±0.224         4   1.209±0.800    0.323
  GSE50013     20    8.342±1.452       20    6.460±2.979    0.017
  GSE40744     39    5.518±1.600       18    5.318±0.891    0.549
  GSE20971     49    7.424±1.716         9   8.383±0.866    0.108
  GSE21362     73    8.324±1.013       73    9.396±0.553    \<0.001
  GSE12717     10    9.370±1.118         6   11.279±0.432   0.001
  GSE6857    241     11.417±1.396    241     11.802±1.054   0.006
  GSE67882       4   0.783±1.976         8   −0.621±0.724   0.094
  GSE65708       6   14.711±1.372        8   16.335±1.210   0.037
  GSE74618   218     2.434±1.074       20    3.254±1.211    0.001
  GSE39678     16    10.300±0.697        8   11.393±0.440   0.001
  GSE21279       4   4.624±1.001       11    4.809±1.862    0.855

SD, standard deviation.

###### 

Association between levels of microRNA-223 and clinicopathological variables in patients with HCC from The Cancer Genome Atlas database.

  Parameter                  n       Mean ± SD       T-value   P-value
  -------------------------- ------- --------------- --------- ---------
  Group                                                        \<0.001
    HCC                      371     9.112±1.436     8.659     
    Normal                     50    10.300±0.811              
  Sex                                                          0.736
    Male                     252     9.095±1.42*6*   0.337     
    Female                   119     9.149±1.462               
  Tumor status                                                 0.625
    Tumor present            111     9.116±1.531     0.489     
    Tumor-free               233     9.037±1.327               
  Family history                                               0.174
    +                        110     9.284±1.479     1.361     
    −                        210     9.053±1.427               
  Risk factors                                                 0.734
    +                        251     9.092±1.435     0.339     
    −                        101     9.149±1.435               
  Other malignancy                                             0.485
    +                          36    9.271±1.446     0.700     
    −                        335     9.095±1.436               
  Inflammation                                                 0.749
    +                        117     9.060±1.418     0.321     
    −                        118     9.000±1.483               
  Ethnicity                                                    0.650
    Hispanic or Latino         18    9.297±1.844     0.461     
    Non-Hispanic or Latino   334     9.094±1.418               
  T stage                                                      0.981
    G I--II                  275     9.105±1.295     0.024     
    G III--IV                  93    9.109±1.812               
  N stage                                                      0.894
    N1                           4   9.190±1.300     0.133     
    NX-N0                    254     9.093±1.446               
  M stage                                                      0.286
    M1                           4   8.324±0.844     1.069     
    MX-M0                    269     9.087±1.423               
  Pathologic stage                                             0.913
    Stage I--II              260     9.084±1.296     0.110     
    Stage III--IV              87    9.108±1.875               
  Vascular invasion                                            0.214
    +                        110     9.227±1.635     1.247     
    −                        206     9.002±1.298               

HCC, hepatocellular carcinoma; T stage, size or direct extent of the primary tumor; N stage, degree of spread to regional lymph nodes; M stage, presence of distant metastasis; SD, standard deviation.

###### 

Characteristics of included studies.

  Author/source, year          Country       Male/female   Sample type   Type of control   Detecting method   (Refs.)
  ---------------------------- ------------- ------------- ------------- ----------------- ------------------ -------------------------
  Khairy *et al*, 2016         Egypt         59/19         Serum         CLD               RT-PCR             ([@b53-mmr-17-02-2211])
  Bhattacharya *et al*, 2016   USA           42/14         Serum         CLD               RT-PCR             ([@b37-mmr-17-02-2211])
  Bhattacharya *et al*, 2016   USA           39/14         Serum         Normal            RT-PCR             ([@b37-mmr-17-02-2211])
  Duo *et al*, 2015            China         80/40         Serum         Normal            RT-PCR             ([@b54-mmr-17-02-2211])
  Duo *et al*, 2015            China         82/38         Serum         CLD               RT-PCR             ([@b54-mmr-17-02-2211])
  Duo *et al*, 2015            China         93/57         Serum         Unclear           RT-PCR             ([@b54-mmr-17-02-2211])
  GSE12717, 2008               USA           NA            Tissue        Unclear           SO                 --
  GSE20971, 2011               France        NA            Tissue        Normal            SO                 --
  GSE21279, 2010               China         NA            Tissue        CLD               HTS                --
  GSE21362, 2011               Japan         NA            Tissue        Unclear           SO                 --
  GSE39678, 2012               South Korea   NA            Tissue        Normal            SO                 --
  GSE41874, 2013               Japan         NA            Tissue        Unclear           SO                 --
  GSE54751, 2014               USA           NA            Tissue        Unclear           RT-PCR             --
  GSE57555, 2015               Japan         NA            Tissue        Unclear           ISO                --
  GSE65708, 2016               China         NA            Serum         CLD               RT-PCR             --
  GSE6857, 2008                USA           NA            Tissue        Unclear           SO                 --
  GSE69580, 2015               Taiwan        NA            Tissue        CLD               ISO                --
  GSE74618, 2016               Spain         NA            Tissue        Unclear           ISO                --
  TCGA, 2016                   NR            NA            Tissue        Normal            HTS                --

RT-PCR, reverse transcription-polymerase chain reaction; CLD, chronic liver disease; ISO, *in situ* oligonucleotide; SO, spotted oligonucleotide; HTS, high throughput sequencing; TCHA, The Cancer Genome Atlas; NA, not applicable.

###### 

Quality assessment of diagnostic accuracy studies.

                               Risk of bias                   Applicability concerns                             
  ---------------------------- -------------- --------- ----- ------------------------ --------- ----- --------- -------------------------
  Khairy *et al*, 2016         Unclear        High      Low   Unclear                  Unclear   Low   Unclear   ([@b53-mmr-17-02-2211])
  Bhattacharya *et al*, 2016   Unclear        Unclear   Low   Low                      Unclear   Low   High      ([@b37-mmr-17-02-2211])
  Duo *et al*, 2015            Unclear        Unclear   Low   Unclear                  Unclear   Low   High      ([@b54-mmr-17-02-2211])

###### 

Diagnostic value of mcroiRNA-223 in 19 individual studies.

  ID    Author/source, year          HCC (n)   Controls (n)   AUC     Sensitivity   Specificity   TP (n)   FP (n)   FN (n)   TN (n)   (Refs.)
  ----- ---------------------------- --------- -------------- ------- ------------- ------------- -------- -------- -------- -------- -------------------------
    1   Khairy *et al*, 2016           23        55           0.680   0.960         0.509           22       27         1      28     ([@b53-mmr-17-02-2211])
    2   Bhattacharya *et al*, 2016     39        17           0.997   0.972         0.941           39         0        0      17     ([@b37-mmr-17-02-2211])
    3   Bhattacharya *et al*, 2016     39        14           1.000   1.000         1.000           38         1        1      13     ([@b37-mmr-17-02-2211])
    4   Duo *et al*, 2015              90        30           NA      0.800         0.900           72         3      18       27     ([@b54-mmr-17-02-2211])
    5   Duo *et al*, 2015              90        30           NA      0.730         0.833           66         5      24       25     ([@b54-mmr-17-02-2211])
    6   Duo *et al*, 2015              90        60           NA      0.719         0.833           65       10       25       50     ([@b54-mmr-17-02-2211])
    7   GSE12717, 2008                 10          6          0.883   0.800         1.000             8        0        2        6    --
    8   GSE20971, 2011                 49          9          0.673   0.531         0.778           26         2      23         7    --
    9   GSE21279, 2010                   4       11           0.568   1.000         0.364             4        7        0        4    --
  10    GSE21362, 2011                 73        73           0.824   0.726         0.904           53         7      20       66     --
  11    GSE39678, 2012                 16          8          0.875   0.750         1.000           12         0        4        8    --
  12    GSE41874, 2013                   6         4          0.625   0.667         0.750             4        1        2        3    --
  13    GSE54751, 2014                 10        10           0.890   0.700         1.000             7        0        3      10     --
  14    GSE57555, 2015                   5       16           0.825   1.000         0.562             5        7        0        9    --
  15    GSE65708, 2016                   6         8          0.813   0.833         0.750             5        2        1        6    --
  16    GSE6857, 2008                241       241            0.597   0.340         0.855           82       35     159      206      --
  17    GSE69580, 2015                   5         5          0.560   0.600         0.800             3        1        2        4    --
  18    GSE74618, 2016               218         20           0.731   0.729         0.750         159          5      59       15     --
  19    TCGA, 2016                   375         50           0.782   0.667         0.860         250          7    125        43     --

HCC, hepatocellular carcinoma; AUC, area under the curve; TP, true positive; FP, false positive; TN, true negative; FN, false negative; NA, not applicable.

###### 

Biological pathways enriched in KEGG of HCC.

  KEGG pathway             Genes                                                              P-value   FDR-value
  ------------------------ ------------------------------------------------------------------ --------- -----------
  MicroRNAs in cancer      KIF23, E2F1, CCNE2, DNMT3A, PDGFRB, IGF2BP1, DNMT1, STMN1, HMGA2   \<0.001     0.037
  Pathways in cancer       E2F1, CCNE2, CDKN2B, ITGA6, PDGFRB, LEF1, BIRC5, EGF, AXIN2        \<0.001     0.634
  Prostate cancer          E2F1, CCNE2, PDGFRB, LEF1, EGF                                     \<0.001     1.031
  Cell cycle               E2F1, CCNE2, CDKN2B, CHEK1, MCM6                                     0.003     3.661
  Small cell lung cancer   E2F1, CCNE2, CDKN2B, ITGA6                                           0.010   10.687
  Endometrial cancer       LEF1, EGF, AXIN2                                                     0.028   26.228
  Wnt signaling pathway    DKK1, SFRP4, LEF1, AXIN2                                             0.032   29.532
  HTLV--I infection        E2F1, CDKN2B, PDGFRB, CHEK1, TCF3                                    0.040   35.953
  Glioma                   E2F1, PDGFRB, EGF                                                    0.042   36.973
  Colorectal cancer        LEF1, BIRC5, AXIN2                                                   0.043   37.802
  Melanoma                 E2F1, PDGFRB, EGF                                                    0.048   41.102

KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.

###### 

Top GO terms significantly enriched with high potential target gene count.

  Category           Term                                                                              Genes                                                                                                               P-value   FDR-value
  ------------------ --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- --------- -----------
  GOTERM_BP_DIRECT   GO:0000281-mitotic cytokinesis                                                    KIF23, CKAP2, STMN1, RACGAP1                                                                                        \<0.001     0.303
  GOTERM_BP_DIRECT   GO:0032467-positive regulation of cytokinesis                                     KIF23, KIF14, RACGAP1, ECT2                                                                                         \<0.001     0.537
  GOTERM_BP_DIRECT   GO:0000122-negative regulation of transcription from RNA polymerase II promoter   SHOX2, E2F1, DNMT3A, DKK1, SIX1, LEF1, WHSC1, SOX9                                                                    0.003     3.933
  GOTERM_BP_DIRECT   GO:0034504-protein localization to nucleus                                        SIX1, COL1A1, SOX9                                                                                                    0.007     9.137
  GOTERM_BP_DIRECT   GO:0060325-face morphogenesis                                                     DKK1, LEF1, COL1A1                                                                                                    0.007     9.833
  GOTERM_BP_DIRECT   GO:0030326-embryonic limb morphogenesis                                           FRAS1, DKK1, LEF1                                                                                                     0.008   11.281
  GOTERM_BP_DIRECT   GO:0030199-collagen fibril organization                                           COL1A1, LOX, MMP11                                                                                                    0.008   11.281
  GOTERM_BP_DIRECT   GO:0010718-positive regulation of epithelial to mesenchymal transition            LEF1, COL1A1, AXIN2                                                                                                   0.008   11.281
  GOTERM_BP_DIRECT   GO:0001942-hair follicle development                                              DKK1, SOX9, LGR5                                                                                                      0.009   12.801
  GOTERM_BP_DIRECT   GO:0000915-actomyosin contractile ring assembly                                   KIF23, RACGAP1                                                                                                        0.010   13.331
  GOTERM_CC_DIRECT   GO:0097149-centralspindlin complex                                                KIF23, RACGAP1, ECT2                                                                                                \<0.001     0.060
  GOTERM_CC_DIRECT   GO:0005874-microtubule                                                            KIF23, KIF14, ARHGEF2, NDRG1, CCT3                                                                                    0.001     1.397
  GOTERM_CC_DIRECT   GO:0030496-midbody                                                                KIF23, KIF14, RACGAP1, ECT2                                                                                           0.006     6.867
  GOTERM_CC_DIRECT   GO:0005813-centrosome                                                             KIF23, CKAP2, DTL, CHEK1, NDRG1, AXIN2                                                                                0.010   10.162
  GOTERM_CC_DIRECT   GO:0005886-plasma membrane                                                        KIF14, CCT3, MMP14, CDH12, DKK1, CNR1, SULF1, RGS5, SORT1, PDGFRB, NDRG1, EGF, AXIN2                                  0.019   19.542
  GOTERM_CC_DIRECT   GO:0005667-transcription factor complex                                           E2F1, SIX1, LEF1, TCF3                                                                                                0.031   29.825
  GOTERM_CC_DIRECT   GO:0048471-perinuclear region of cytoplasm                                        NOX4, XRCC3, STC2, SORT1, NDRG1                                                                                       0.044   39.035
  GOTERM_CC_DIRECT   GO:0005634-nucleus                                                                E2F1, NOX4, CCNF, ATAD2, WHSC1, PBK, HMGA2, SOX9, ECT2, MCM6, CCNE2, SHOX2, GLUL, HEY1, SIX1, TXNRD1, NDRG1, TCF3     0.044   39.179
  GOTERM_CC_DIRECT   GO:0005654-nucleoplasm                                                            KIF23, DNMT3A, XRCC3, CDKN2B, DTL, ATAD2, CHEK1, RACGAP1, AXIN2, SOX9, MCM6                                           0.044   39.550
  GOTERM_MF_DIRECT   GO:0005524-ATP binding                                                            KIF23, KIF14, GLUL, XRCC3, MSH2, PFKFB2, ABCC4, PDGFRB, ATAD2, CHEK1, PBK, CCT3, MCM6                                 0.003     3.662
  GOTERM_MF_DIRECT   GO:0003682-chromatin binding                                                      DNMT3A, SIX1, LEF1, ATAD2, WHSC1, SOX9                                                                                0.008     8.509
  GOTERM_MF_DIRECT   GO:0070016-armadillo repeat domain binding                                        LEF1, AXIN2                                                                                                           0.021   21.262
  GOTERM_MF_DIRECT   GO:0035326-enhancer binding                                                       LEF1, SOX9                                                                                                            0.030   28.444
  GOTERM_MF_DIRECT   GO:0005096-GTPase activator activity                                              RGS5, RACGAP1, AXIN2, ECT2                                                                                            0.039   35.353

FDR, false discovery rate; GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

Ten prominent protein-protein interaction nodes according to the Search Tool for the Retrieval of Interacting Genes.

  Node 1    Node 2   Co-expression   Experimentally determined interaction   Database annotated   Automated textmining   Combined score
  --------- -------- --------------- --------------------------------------- -------------------- ---------------------- ----------------
  DNMT1     DNMT3A   0               0.798                                   0.9                  0.987                  0.999
  RACGAP1   ECT2     0.288           0.914                                   0.9                  0.907                  0.999
  RACGAP1   KIF23    0.578           0.996                                   0.9                  0.979                  0.999
  KIF23     ECT2     0.245           0.564                                   0.9                  0.966                  0.998
  E2F1      CCNE2    0               0.363                                   0.9                  0.735                  0.981
  BIRC5     KIF23    0.161           0                                       0.9                  0.738                  0.976
  AXIN2     LEF1     0               0.110                                   0.9                  0.751                  0.976
  RACGAP1   BIRC5    0.173           0                                       0.9                  0.714                  0.974
  CHEK1     MCM6     0.093           0.207                                   0.9                  0.562                  0.964
  DNMT1     E2F1     0.070           0.564                                   0.9                  0.116                  0.959

DNMT, DNA methyltransferase; RACGAP1, Rac GTPase-activating protein 1; KIF23, kinesin family member 23; BIRC5, baculoviral IAP repeat containing 5; CHEK1, checkpoint kinase 1; CCNE2, cyclin E2; LEF1, lymphoid enhancer-binding factor 1; MCM6, minichromosome maintenance complex component 6.
